Specifically, we tested whether IRE in combination with anti-CTLA-4 would promote SPAS-1+ CD8+ T cell expansion and regression of residual primary tumor growth in the TRAMP-C2 model (Fig. 4a). The gene discussed is SPATA19; the disease is neoplasm.